---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-009406"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2022-05-26T23:59:59+00:00"
generated_at: "2026-06-25T06:35:53.736413+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Protalix announces five poster presentations at Fabry Disease conference

## Summary
- Posters cover pegunigalsidase alfa data from BALANCE, BRIDGE, BRIGHT, and extension studies.
- Conference is the 7th Update on Fabry Disease in Würzburg, Germany, May 29-31, 2022.
- Posters and abstracts will be posted on Protalix's website under Investors/Presentations.
- Data include 24-month renal function results from Phase III BALANCE study.
- No specific efficacy or safety numbers were disclosed in the press release.

## SEC filing metadata
- accession: 0001558370-22-009406
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2022-05-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837022009406/0001558370-22-009406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837022009406/plx-20220526x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-009406
- JSON: https://secwatch.observer/filing/0001558370-22-009406.json
- Plain text: https://secwatch.observer/filing/0001558370-22-009406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.